MediPurpose Publishes Heelstick Device Cut Profile Comparative Study White Paper
Results Indicate New babyLance(r) Delivers an Ideal Incision
Atlanta, GA, September 01, 2012 --(PR.com)-- MediPurpose(r), a master distributor and manufacturer of medical devices, today announced the publication of its latest white paper, Reinventing a Better babyLance(r) Infant Heel Incision Device: Heelstick Cut Profile Comparative Study.
Earlier this year, MediPurpose conducted cut profile studies of its new, redesigned babyLance, the BD Quikheel(tm), Cardinal Health gentleheel(tm) and ITC Tenderfoot(r). The white paper indicates that babyLance most consistently met the definition of what could be considered the ideal infant heel incision.
In its goal of designing a heelstick device that is easy to use, meets CLSI guidelines, and delivers an ideal incision, MediPurpose believes that the new babyLance fulfilled its ambitions, said MediPurpose founder and CEO Patrick Yi. Along with meeting CLSI LA4-A5 guidelines, visual examination of babyLance's cut profile demonstrated the smoothest, cleanest incision.
"Throughout the redesign process, we routinely validated babyLance's new design," said Yi. "As a result, we are confident that our new neonatal heelstick device will satisfy the unique needs of both our end-user customers and distribution partners."
Yi said that his company's confidence is fostered by the knowledge that its new infant heelstick device:
* Is designed with intensive input from a diverse range of highly qualified users.
* Provides a preferred pull trigger activation mechanism that is comfortable and easy to use.
* Is assured to provide safety and quality from a proven and trusted manufacturer with worldwide distribution channels.
Additionally, Yi said "that the results further validate MediPurpose's medical product innovation process and capabilities."
Along with its new white paper, MediPurpose has recently published other white papers related to the redesign of babyLance, including papers that outlined user requirements and summarized a trigger activation survey conducted at the NANN 2011 conference.
About babyLance(r) Infant Heel Incision Devices
The new babyLance infant heel incision device is a fully redesigned iteration of MediPurpose's original safe, easy and effective heelstick device.
Used by neonatal caregivers to collect blood samples from infants, the new babyLance features an ergonomic design to provide a secure and stable grip.
Combined with a redesigned trigger mechanism, the heelstick device is easy to activate, helping to deliver a consistent incision without damaging the baby's tender nerve fibers.
babyLance heelstick devices are available in two models:
* The babyLance BLN (Newborn), which delivers an incision depth of 1.00 mm.
* The babyLance BLP (Preemie), which delivers an incision depth of 0.85 mm.
To download the white papers, please visit http://www.medipurpose.com/downloads .
For more information about babyLance -- including pricing and no-cost product sample requests -- please visit http://www.medipurpose.com/babylance .
About MediPurpose
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance(r) heel incision device, SurgiLance(r) safety lancet and MediPlus(tm) advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and distributors.
MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com.
Earlier this year, MediPurpose conducted cut profile studies of its new, redesigned babyLance, the BD Quikheel(tm), Cardinal Health gentleheel(tm) and ITC Tenderfoot(r). The white paper indicates that babyLance most consistently met the definition of what could be considered the ideal infant heel incision.
In its goal of designing a heelstick device that is easy to use, meets CLSI guidelines, and delivers an ideal incision, MediPurpose believes that the new babyLance fulfilled its ambitions, said MediPurpose founder and CEO Patrick Yi. Along with meeting CLSI LA4-A5 guidelines, visual examination of babyLance's cut profile demonstrated the smoothest, cleanest incision.
"Throughout the redesign process, we routinely validated babyLance's new design," said Yi. "As a result, we are confident that our new neonatal heelstick device will satisfy the unique needs of both our end-user customers and distribution partners."
Yi said that his company's confidence is fostered by the knowledge that its new infant heelstick device:
* Is designed with intensive input from a diverse range of highly qualified users.
* Provides a preferred pull trigger activation mechanism that is comfortable and easy to use.
* Is assured to provide safety and quality from a proven and trusted manufacturer with worldwide distribution channels.
Additionally, Yi said "that the results further validate MediPurpose's medical product innovation process and capabilities."
Along with its new white paper, MediPurpose has recently published other white papers related to the redesign of babyLance, including papers that outlined user requirements and summarized a trigger activation survey conducted at the NANN 2011 conference.
About babyLance(r) Infant Heel Incision Devices
The new babyLance infant heel incision device is a fully redesigned iteration of MediPurpose's original safe, easy and effective heelstick device.
Used by neonatal caregivers to collect blood samples from infants, the new babyLance features an ergonomic design to provide a secure and stable grip.
Combined with a redesigned trigger mechanism, the heelstick device is easy to activate, helping to deliver a consistent incision without damaging the baby's tender nerve fibers.
babyLance heelstick devices are available in two models:
* The babyLance BLN (Newborn), which delivers an incision depth of 1.00 mm.
* The babyLance BLP (Preemie), which delivers an incision depth of 0.85 mm.
To download the white papers, please visit http://www.medipurpose.com/downloads .
For more information about babyLance -- including pricing and no-cost product sample requests -- please visit http://www.medipurpose.com/babylance .
About MediPurpose
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance(r) heel incision device, SurgiLance(r) safety lancet and MediPlus(tm) advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and distributors.
MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com.
Contact
MediPurpose
Derek Rudnak
888-808-6494
www.medipurpose.com
Derek Rudnak
888-808-6494
www.medipurpose.com
Contact
Categories